Luke R G Pike
Overview
Explore the profile of Luke R G Pike including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
543
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Imber B, Yu K, Abida W, Pike L, Grkovski M, Kaley T, et al.
J Nucl Med
. 2025 Mar;
PMID: 40049744
No abstract available.
2.
Gaeta B, Eichholz J, Walch H, Ilica A, Ilica A, Boe L, et al.
Int J Radiat Oncol Biol Phys
. 2025 Feb;
PMID: 39929348
Purpose: Precision medicine according to molecularly defined subgroups offers great potential to improve outcomes for patients with metastatic lung adenocarcinoma. This study describes clinical outcomes and the impact of co-occurring...
3.
Perlow H, Raleigh D, Wang T, Pollom E, Milano M, Breen W, et al.
Int J Radiat Oncol Biol Phys
. 2024 Dec;
PMID: 39701546
Purpose: Meningiomas are the most common primary intracranial tumor. Somatostatin receptor 2 is almost universally expressed in meningioma tissue. For patients who require adjuvant radiation, somatostatin receptor based (68)Ga-DOTATATE positron...
4.
Hockemeyer K, Rusthoven C, Pike L
Cancers (Basel)
. 2024 Nov;
16(22.
PMID: 39594735
Lung cancer, both non-small cell and small cell, harbors a high propensity for spreading to the central nervous system. Radiation therapy remains the backbone of the management of brain metastases....
5.
Rusthoven C, Miao E, Boe L, Pike L
J Clin Oncol
. 2024 Nov;
43(6):762-763.
PMID: 39546734
No abstract available.
6.
Gui C, Walch H, Mueller K, Boe L, Ilica A, Strong J, et al.
J Neurosurg
. 2024 Aug;
142(2):443-453.
PMID: 39213675
Objective: Brain metastases (BM) from colorectal cancer (CRC) are associated with dismal prognosis. When BM-directed therapy is considered, better methods are needed to identify patients at risk of poor oncological...
7.
Liu S, Erazo T, Jee J, Arfe A, Gupta A, Pike L, et al.
Eur J Cancer
. 2024 Aug;
210:114257.
PMID: 39151324
Introduction: No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting....
8.
Ma J, Del Balzo L, Walch H, Khaleel S, Knezevic A, Flynn J, et al.
Eur Urol Oncol
. 2024 Aug;
PMID: 39107179
Background: Molecular profiles of renal cell carcinoma (RCC) brain metastases (BMs) are not well characterized. Effective management with locoregional therapies, including stereotactic radiosurgery (SRS), is critical as systemic therapy advancements...
9.
Pike L, Miao E, Boe L, Patil T, Imber B, Myall N, et al.
J Clin Oncol
. 2024 Jul;
42(30):3606-3617.
PMID: 39047224
Purpose: Newer-generation tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor () mutations and anaplastic lymphoma kinase () rearrangements have demonstrated high CNS activity....
10.
Mazzone P, Bach P, Carey J, Schonewolf C, Bognar K, Ahluwalia M, et al.
Cancer Discov
. 2024 Jun;
14(11):2224-2242.
PMID: 38829053
Lung cancer screening via annual low-dose computed tomography has poor adoption. We conducted a prospective case-control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung...